Join
Live feed
·
PRReleasevia Quantisnow
Anavex Life Sciences Corp. logo

ANAVEX®2-73 (Blarcamesine) AVATAR Phase 3 Trial met Primary and Secondary Efficacy Endpoints for the Treatment of Adult Patients with Rett Syndrome

ByQuantisnow·Wall Street's wire, on your screen.
AVXL· Anavex Life Sciences Corp.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track AVXL (Anavex Life Sciences Corp.) and more on Quantisnow.